Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes.

Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes.

Few trials of glucose-lowering drugs or strategies in people with type 2 diabetes have investigated cardiovascular outcomes, even though most patients die from cardiovascular causes despite the beneficial effects of lipid-reducing and blood pressure-lowering treatments. The evidence-based reduction...

Szczegółowa specyfikacja

Opis bibliograficzny
Główni autorzy:	Holman, R, Sourij, H, Califf, R
Format:	Journal article
Język:	English
Wydane:	Lancet 2014

Podobne zapisy

Cardiovascular outcome trials of glucose-lowering strategies in type 2 diabetes--Authors' reply.
od: Holman, R, i wsp.
Wydane: (2014)

People at increased risk of cardiovascular disease screened for the NAVIGATOR trial frequently have undiagnosed diabetes or impaired glucose tolerance
od: Califf, R, i wsp.
Wydane: (2003)

Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial.
od: Califf, R, i wsp.
Wydane: (2008)

Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease
od: Green, J, i wsp.
Wydane: (2013)

Rationale and design of the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)
od: Bethel, M, i wsp.
Wydane: (2009)

Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease.
od: Green, J, i wsp.
Wydane: (2013)

Untitled reply
od: Holman, R, i wsp.
Wydane: (2014)

Time-dependent event accumulation in a cardiovascular outcome trial of patients with type 2 diabetes and established atherosclerotic cardiovascular disease
od: M. Angelyn Bethel, i wsp.
Wydane: (2023-03-01)

Improving glucose control and cardiovascular risk in general practice Type 2 diabetes.
od: Potts, N, i wsp.
Wydane: (2003)

Correspondence on sitagliptin and cardiovascular outcomes in type 2 diabetes
od: Holman, R, i wsp.
Wydane: (2015)

Are lower fasting plasma glucose levels at diagnosis of type 2 diabetes associated with improved outcomes?: U.K. prospective diabetes study 61.
od: Colagiuri, S, i wsp.
Wydane: (2002)

Baseline characteristics of the Nateglinide and Valsartan Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial population: comparison with other diabetes prevention trials.
od: Krum, H, i wsp.
Wydane: (2010)

Risk factors for fatal and non-fatal cardiovascular events in 9306 subjects in the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial
od: Mcmurray, J, i wsp.
Wydane: (2011)

Glucose-Lowering Therapy beyond Insulin in Type 1 Diabetes: A Narrative Review on Existing Evidence from Randomized Controlled Trials and Clinical Perspective
od: Felix Aberer, i wsp.
Wydane: (2022-05-01)

Role of lifestyle and oral anti-diabetic agents to prevent type 2 diabetes mellitus and cardiovascular disease.
od: Bethel, M, i wsp.
Wydane: (2007)

Sex Differences in Cardiovascular Effectiveness of Newer Glucose‐Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus
od: Valeria Raparelli, i wsp.
Wydane: (2020-01-01)

Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the Nateglinide and Valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial
od: Preiss, D, i wsp.
Wydane: (2012)

Age, sex, race, BMI, and duration of diabetes differences in cardiovascular outcomes with glucose lowering drugs in type 2 diabetes: A systematic review and meta-analysis
od: Alhassane Diallo, i wsp.
Wydane: (2022-12-01)

Sitagliptin and cardiovascular outcomes in type 2 diabetes - author's reply
od: Holman, RR, i wsp.
Wydane: (2015)

Women develop diabetes at higher BMIs than men.
od: Sourij, H, i wsp.
Wydane: (2012)

Women develop diabetes at higher BMIs than men
od: Sourij, H, i wsp.
Wydane: (2012)

Ethnic Variations in Cardiovascular and Renal Outcomes From Newer Glucose‐Lowering Drugs: A Meta‐Analysis of Randomized Outcome Trials
od: Huilin Tang, i wsp.
Wydane: (2023-05-01)

Continuous glucose monitoring detected hypoglycaemia in the Treating to Target in Type 2 Diabetes Trial (4-T)
od: Levy, J, i wsp.
Wydane: (2017)

Intensive glucose control and macrovascular outcomes in type 2 diabetes.
od: Turnbull, F, i wsp.
Wydane: (2009)

TYPE 2 DIABETES AND CARDIOVASCULAR COMPLICATIONS: IS IT POSSIBLE TO IMPROVE PROGNOSIS BY GLUCOSE LOWERING THERAPY?
od: Zh. D. Kobalava, i wsp.
Wydane: (2018-09-01)

The impact of innovative glucose-lowering drugs on the course and outcome of COVID-19 in patients with type 2 diabetes mellitus
od: T. N. Markova, i wsp.
Wydane: (2024-05-01)

Optimizing blood glucose control in type 2 diabetes: an approach based on fasting blood glucose measurements.
od: Holman, R, i wsp.
Wydane: (1988)

Predicting post one-year durability of glucose-lowering monotherapies in patients with new-onset type 2 diabetes
od: Agbaje, O, i wsp.
Wydane: (2017)

Adding value to the experience of attending a diabetes clinic appointment: provision of personalised 10 year cardiovascular disease (CVD) risk estimates
od: Adamson, R, i wsp.
Wydane: (2013)

Follow-up of Intensive Glucose Control in Type 2 Diabetes Reply
od: Holman, R, i wsp.
Wydane: (2009)

Glycemia control and glucose-lowering therapy in patients with type 2 diabetes mellitus and cardiovascular disease (review of multicenter randomized trials)
od: Sergey V. Kakorin, i wsp.
Wydane: (2016-07-01)

Predictors of stroke in patients with impaired glucose tolerance: results from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial.
od: Preiss, D, i wsp.
Wydane: (2013)

Time-resolved trajectory of glucose lowering medications and cardiovascular outcomes in type 2 diabetes: a recurrent neural network analysis
od: Enrico Longato, i wsp.
Wydane: (2022-08-01)

Impact of FDA Guidance for Developing Diabetes Drugs on Trial Design: From Policy to Practice
od: Bethel, A, i wsp.
Wydane: (2011)

Impact of FDA guidance for developing diabetes drugs on trial design: from policy to practice.
od: Bethel, M, i wsp.
Wydane: (2012)

Cardiovascular risks in type 2 diabetes and the interpretation of cardiovascular outcome trials
od: Hinnen D, i wsp.
Wydane: (2019-04-01)

Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic review and meta-analysis.
od: Chun-Xing Li, i wsp.
Wydane: (2021-01-01)

A cardiovascular risk calculator for type 2 diabetes
od: Coleman, R, i wsp.
Wydane: (2005)

Rationale and design of the EXenatide study of cardiovascular event lowering (EXSCEL) trial
od: Holman, R, i wsp.
Wydane: (2015)

International variation in outcomes among people with cardiovascular disease or cardiovascular risk factors and impaired glucose tolerance: Insights from the NAVIGATOR Trial.
od: Dos Santos, M, i wsp.
Wydane: (2017)